Aldosterone blocks adrenal compensatory hypertrophy in the rat

1984 ◽  
Vol 246 (4) ◽  
pp. E306-E310 ◽  
Author(s):  
W. E. Grizzle ◽  
N. E. Dunlap
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Negative Feedback ◽  
Low Dose ◽  
Feedback System ◽  
Compensatory Hypertrophy ◽  
Anesthetized Rats ◽  
Data Support

We report that adrenal compensatory hypertrophy occurs in intact and hypophysectomized anesthetized rats as well as in rats in which endogenous ACTH is suppressed by administration of dexamethasone or of dexamethasone plus low-dose ACTH. However, adrenal compensatory hypertrophy is blocked in intact and hypophysectomized animals when aldosterone alone or the combination of aldosterone, dexamethasone, and ACTH is administered using Alzet pumps. These data support previous reports that questioned the validity of the hypothesis that adrenal compensatory hypertrophy is controlled by the glucocorticoid-ACTH negative feedback system. These results require modification of current hypotheses concerning the mechanism of adrenal compensatory hypertrophy to allow for a central nervous system or other effect of aldosterone.

scholarly journals Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys

2019 ◽  
Vol 202 (12) ◽  
pp. 3412-3422 ◽  
Author(s):  
Susanta Mondal ◽  
Suresh B. Rangasamy ◽  
Avik Roy ◽  
Sridevi Dasarathy ◽  
Jeffrey H. Kordower ◽  
...  
Keyword(s):  
Central Nervous System ◽  
T Cells ◽  
Nervous System ◽  
Low Dose ◽  
Antiretroviral Drug ◽  
The Central Nervous System

scholarly journals The impact of high and low dose ionising radiation on the central nervous system

Redox Biology ◽  
2016 ◽  
Vol 9 ◽  
pp. 144-156 ◽  
Author(s):  
Calina Betlazar ◽  
Ryan J. Middleton ◽  
Richard B. Banati ◽  
Guo-Jun Liu
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Low Dose ◽  
Ionising Radiation ◽  
The Central Nervous System ◽  
The Impact

scholarly journals ML-13 Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab

2021 ◽  
Vol 3 (Supplement_6) ◽  
pp. vi24-vi24
Author(s):  
Masasuke Ohno ◽  
Syunichiro Kuramitsu ◽  
Syohei Ito ◽  
Masayuki Kimata ◽  
Takumi Asai ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Central Nervous System ◽  
Nervous System ◽  
Malignant Lymphoma ◽  
Low Dose ◽  
Central Nervous System Lymphoma ◽  
Stereotactic Brain Biopsy ◽  
Dose Methotrexate ◽  
First Case ◽  
Risk Of Cancer

Abstract Background: Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, the occurrence of primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rare. In recent years, there has been concern that biological disease-modifying antirheumatic drugs (DMRADs), which are widely administered to patients with RA, may increase the risk of developing cancer. We report the first case of PCNSL in a patient with RA who was treated with the biological DMRADs, tocilizumab. Case description: A 70-year-old man, who was diagnosed with RA in 2010 was treated with low-dose methotrexate from 2010 to 2015. He was started on tocilizumab in 2012. In 2018, he suffered from gait disturbance and was diagnosed with lumbar spinal stenosis. He underwent L2/3 posterior fusion surgery, but his paraplegia gradually deteriorated. Two months after the surgery, a head Gd-MRI showed multiple contrast-enhanced lesions in the basal ganglia and brain stem. A stereotactic brain biopsy was performed and DLBCL was diagnosed, and finally PCNSL was diagnosed because of no neoplastic lesions in other organs. He was treated with 5 courses of MTX 3.5g/m2 with rituximab and has been in remission for 23 months. He has maintained an independent life with residual paraplegia, but his ADLs gradually worsened. He was restarted on tocilizumab with a diagnosis of worsening RA. Conclusion: Low-dose methotrexate and biological DMRADs including tocilizumab, have been concerned to increase the risk of cancer in patients with RA, but there is no solid evidence. Since it has been a short time since the use of biological DMRADs, further accumulation of cases and careful follow-up are necessary.

Sign in / Sign up

Export Citation Format

Share Document